FDA Recalls TIROSINT Levothyroxine Sodium Lot 220853 for Subpotency
IBSA Pharma Inc. recalled TIROSINT levothyroxine sodium lot 220853 nationwide due to subpotency. The oral solution may contain less active ingredient than labeled, potentially affecting thyroid hormone replacement therapy.
- Product
- TIROSINT — TIROSINT (LEVOTHYROXINE SODIUM)
- Category
- Drug
- Distribution
- Distributed nationwide